DK1255544T3 - Mucin-syntese-inhibitorer - Google Patents

Mucin-syntese-inhibitorer

Info

Publication number
DK1255544T3
DK1255544T3 DK01906804T DK01906804T DK1255544T3 DK 1255544 T3 DK1255544 T3 DK 1255544T3 DK 01906804 T DK01906804 T DK 01906804T DK 01906804 T DK01906804 T DK 01906804T DK 1255544 T3 DK1255544 T3 DK 1255544T3
Authority
DK
Denmark
Prior art keywords
synthesis inhibitors
mucin synthesis
mucin
inhibitors
synthesis
Prior art date
Application number
DK01906804T
Other languages
Danish (da)
English (en)
Inventor
Yuhong Zhou
Roy C Levitt
Nicholas C Nicolaides
Steve Jones
Mike Mclane
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of DK1255544T3 publication Critical patent/DK1255544T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK01906804T 2000-01-31 2001-01-31 Mucin-syntese-inhibitorer DK1255544T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17912700P 2000-01-31 2000-01-31
US19311100P 2000-03-30 2000-03-30
US23078300P 2000-09-07 2000-09-07
US24213400P 2000-10-23 2000-10-23
US25205200P 2000-11-20 2000-11-20
PCT/US2001/003078 WO2001054685A1 (en) 2000-01-31 2001-01-31 Mucin synthesis inhibitors

Publications (1)

Publication Number Publication Date
DK1255544T3 true DK1255544T3 (da) 2007-09-17

Family

ID=27539006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01906804T DK1255544T3 (da) 2000-01-31 2001-01-31 Mucin-syntese-inhibitorer

Country Status (13)

Country Link
US (2) US6737427B2 (https=)
EP (1) EP1255544B1 (https=)
JP (1) JP2004507444A (https=)
AR (1) AR042578A1 (https=)
AT (1) ATE355836T1 (https=)
AU (2) AU2001234671B2 (https=)
CA (1) CA2398642A1 (https=)
CY (1) CY1106643T1 (https=)
DE (1) DE60127098T2 (https=)
DK (1) DK1255544T3 (https=)
ES (1) ES2282235T3 (https=)
PT (1) PT1255544E (https=)
WO (1) WO2001054685A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345051B2 (en) * 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
ES2282235T3 (es) * 2000-01-31 2007-10-16 Genaera Corporation Inhibidores de la sintesis de la mucina.
US8474460B2 (en) 2000-03-04 2013-07-02 Pulmonx Corporation Implanted bronchial isolation devices and methods
US6904909B2 (en) 2000-03-04 2005-06-14 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US6679264B1 (en) 2000-03-04 2004-01-20 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US20030059434A1 (en) * 2000-08-09 2003-03-27 Andrew Grupe Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions
US7011094B2 (en) 2001-03-02 2006-03-14 Emphasys Medical, Inc. Bronchial flow control devices and methods of use
US20030050648A1 (en) 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
AU2002347900B8 (en) 2001-10-11 2006-01-12 Emphasys Medical, Inc. Bronchial flow control devices and methods of use
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
US6929637B2 (en) 2002-02-21 2005-08-16 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
WO2003075796A2 (en) 2002-03-08 2003-09-18 Emphasys Medical, Inc. Methods and devices for inducing collapse in lung regions fed by collateral pathways
US20030216769A1 (en) 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US20040059263A1 (en) 2002-09-24 2004-03-25 Spiration, Inc. Device and method for measuring the diameter of an air passageway
DE60323502D1 (de) 2002-07-26 2008-10-23 Emphasys Medical Inc Bronchiale durchflussvorrichtung mit einer membranabdichtung
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7100616B2 (en) 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
MXPA05012728A (es) 2003-05-28 2006-02-13 Wyeth Corp Clca-1 soluble y antagonistas para el clca-1.
EP1633734A2 (en) * 2003-06-19 2006-03-15 Genaera Corporation Mucin synthesis inhibitors
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
JP2008507368A (ja) * 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
US7771472B2 (en) 2004-11-19 2010-08-10 Pulmonx Corporation Bronchial flow control devices and methods of use
EP1827479A1 (en) * 2004-12-09 2007-09-05 Ingenium Pharmaceuticals AG Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion
WO2006075172A2 (en) * 2005-01-13 2006-07-20 University Of Dundee Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
US8876791B2 (en) 2005-02-25 2014-11-04 Pulmonx Corporation Collateral pathway treatment using agent entrained by aspiration flow current
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
EP3669878A1 (en) 2006-08-10 2020-06-24 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2008112141A1 (en) * 2007-03-07 2008-09-18 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
US8136230B2 (en) 2007-10-12 2012-03-20 Spiration, Inc. Valve loader method, system, and apparatus
GB0905954D0 (en) * 2009-04-06 2009-05-20 E Therapeutics Plc Treatment of exacerbations of asthma
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012134965A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
WO2013044267A1 (en) 2011-09-23 2013-03-28 Pulmonx, Inc. Implant loading device and system
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2015182565A1 (ja) * 2014-05-27 2015-12-03 リンク・ジェノミクス株式会社 肺疾患治療剤
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168313A (en) 1978-02-21 1979-09-18 Sebastian Bago Phthalidyl 2-(3'-trifluoromethyl-anilino)-pyridine-3-carboxylate and its salts
US4515980A (en) * 1983-07-11 1985-05-07 Sterling Drug Inc. Substituted aminobenzoates, their preparation and use
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
DE3682136D1 (de) 1985-07-31 1991-11-28 Hoechst Ag N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
DE3608726A1 (de) * 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
US5733748A (en) 1995-06-06 1998-03-31 Human Genome Sciences, Inc. Colon specific genes and proteins
WO1997003659A1 (de) * 1995-07-20 1997-02-06 Uwe Juergens Verwendung eines nicht-steroidalen antiphlogistikums zur topischen und systemischen behandlung der akuten und chronischen polypoiden rhinosinusitis
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
NZ336659A (en) * 1997-01-08 2001-01-26 Upjohn Co Pharmaceutically active pyrimido[4,5-b]indoles
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
CA2290509A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
AU2674399A (en) * 1998-02-11 1999-08-30 Regents Of The University Of California, The Compositions and methods for the inhibition of muc-5 mucin gene expression
CA2321664C (en) 1998-03-03 2009-06-02 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
JP2002534380A (ja) * 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
HUP0105092A3 (en) * 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7965000A (en) * 1999-09-27 2001-04-30 Jun-Suk Oh Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same
ES2282235T3 (es) 2000-01-31 2007-10-16 Genaera Corporation Inhibidores de la sintesis de la mucina.
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
US6737427B2 (en) 2004-05-18
AR042578A1 (es) 2005-06-29
JP2004507444A (ja) 2004-03-11
AU2001234671B2 (en) 2006-05-18
DE60127098D1 (de) 2007-04-19
ATE355836T1 (de) 2007-03-15
US20040254096A1 (en) 2004-12-16
ES2282235T3 (es) 2007-10-16
CA2398642A1 (en) 2001-08-02
US7504409B2 (en) 2009-03-17
US20010041685A1 (en) 2001-11-15
CY1106643T1 (el) 2012-01-25
PT1255544E (pt) 2007-06-15
AU3467101A (en) 2001-08-07
EP1255544B1 (en) 2007-03-07
EP1255544A4 (en) 2005-02-02
DE60127098T2 (de) 2007-11-29
WO2001054685A1 (en) 2001-08-02
EP1255544A1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
DK1255544T3 (da) Mucin-syntese-inhibitorer
ATE524441T1 (de) Vla-4-inhibitoren
DE60117597D1 (de) Aufweitvorrichtung
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
NO20024686D0 (no) Avleiringsfjerning
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
NO20022353D0 (no) Hylle
DE60142401D1 (de) Verbindungsverfahren
PT1339695E (pt) Inibidores da farnesiltransferase
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
DK1246791T3 (da) Aminomethyl-phenyl-cyklohexanonderivater
DE60027792D1 (de) Schmuckstück
AR027982A1 (es) Aril- y heteroarilsulfonatos
AR028075A1 (es) Inhibidores de la peptido-desformilasa
DE60132468D1 (de) Alen-lanosterol zyklase inhibitoren
IS6697A (is) Kassi
DE60132509D1 (de) Stopuhr
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater